|
KMID : 1146120170030010014
|
|
Journal of Mucopolysaccharidosis and Rare Diseases
2017 Volume.3 No. 1 p.14 ~ p.19
|
|
|
Newborn Screening for Lysosomal Storage Diseases in Taiwan
|
|
Lin Hsiang-Yu
Chuang Chih-Kuang
Lin Shuan-Pei
|
|
|
Abstract
|
|
|
|
Lysosomal storage diseases (LSDs) are a group of rare inherited metabolic disorders caused by the deficiency of specific lysosomal enzymes and subsequent accumulation of substrates. Enzyme deficiency leads to progressive intra-lysosomal accumulation of the incompletely degraded substances, which cause dysfunction and destruction of the cell and eventually multiple organ damage. Patients have a broad spectrum of clinical phenotypes which are generally not specific for some LSDs, leading to missed or delayed diagnosis. Due to the availability of treatment including enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation for some LSDs, early diagnosis is important. ERT products have been approved with optimal outcomes for some LSDs in the recent decades, including Gaucher, Fabry, mucopolysaccharidosis (MPS) I, Pompe, MPS VI, MPS II, and MPS IVA diseases. ERT can stabilize the clinical condition, prevent disease progression, and improve the long-term outcome of these diseases, especially if started prior to irreversible organ damage. Based on the availability of therapy and suitable screening methods in the recent years, some LSDs, including Pompe, Fabry, Gaucher, MPS I, MPS II, and MPS VI diseases have been incorporated into nationwide newborn screening panels in Taiwan.
|
|
|
KEYWORD
|
|
|
Enzyme replacement therapy, Fluorimetry, Hematopoietic stem cell transplantation, Lysosomal storage disease, Newborn screening, Tandem mass spectrometry
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|